

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	<b>ZELDA THERAPEUTICS LIMITED</b>
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Peterson
Date of last notice	17 November 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	i. Jason Peterson and Lisa Peterson <J&L Peterson S/F A/C> (Beneficiary) ii. Celtic Capital Pty Ltd <The Celtic Capital A/C> (Director/Shareholder) iii. Celtic Capital Pte Ltd <Investment 1 A/C> (Director/Shareholder) iv. Professional Payment Services Pty Ltd (Director/Shareholder) v. CPS Capital Group Pty Ltd (Director/Shareholder) vi. Sunset Capital Management Pty Ltd <Sunset Superfund> (Beneficiary)
Date of change	14 December 2017
No. of securities held prior to change	i. 52,459,017 ordinary shares i. 8,000,000 options (\$0.03125; 17/11/2021) ii. 11,200,000 ordinary shares iii. 5,800,000 ordinary shares iv. 538,231 ordinary shares v. 4,800,000 ordinary shares vi. 5,495,141 ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

Class	Ordinary shares
Number acquired	Nil
Number disposed	5,495,141
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash due to internal restructure. Estimated value \$0.09 per share (5 day VWAP).
No. of securities held after change	<ul style="list-style-type: none"> <li>i. 52,459,017 ordinary shares</li> <li>i. 8,000,000 options (\$0.03125; 17/11/2021)</li> <li>ii. 11,200,000 ordinary shares</li> <li>iii. 5,800,000 ordinary shares</li> <li>iv. 538,231 ordinary shares</li> <li>v. 4,800,000 ordinary shares</li> </ul>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off-market trade

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

+ See chapter 19 for defined terms.